» Articles » PMID: 26018028

Hypoxia Enhances Cholangiocarcinoma Invasion Through Activation of Hepatocyte Growth Factor Receptor and the Extracellular Signal‑regulated Kinase Signaling Pathway

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2015 May 29
PMID 26018028
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia is associated with tumor progression and poor prognosis in several cancer types. The present study aimed to examine the contribution of hypoxia (1% O2) to cancer progression in a cholangiocarcinoma cell line, RMCCA‑1. The molecular basis of the hypoxic response pathway was investigated. The results showed that hypoxia significantly accelerated cancer cell proliferation and enhanced cell invasion (P<0.05). By using receptor tyrosine kinase and intracellular signaling antibody array kits, an increased phosphorylation/activation of a number of signaling molecules, particularly hepatocyte growth factor receptor (Met) and extracellular signal‑regulated kinase (ERK) 1/2, was identified. Inhibition of Met and ERK by small hairpin RNA and U0126, respectively, significantly inhibited hypoxia‑induced the invasive potential of RMCCA‑1 cells (P<0.05). However, according to immunohistochemical analysis, hypoxia‑inducible factor‑1α expression was not correlated with cancer staging or tumor differentiation in 44 samples of cholangicarcinoma cases. The findings of the present study emphasized the importance of Met/ERK pathway activation as a key molecular event that may be responsible for a more invasive phenotype in hypoxic tumors and suggest Met as a potential target for the treatment of cholangiocarcinoma.

Citing Articles

Organoids and spheroids: advanced models for liver cancer research.

Pastore M, Giachi A, Spinola-Lasso E, Marra F, Raggi C Front Cell Dev Biol. 2025; 12():1536854.

PMID: 39850799 PMC: 11754960. DOI: 10.3389/fcell.2024.1536854.


Single-cell RNA sequencing identifies critical transcription factors of tumor cell invasion induced by hypoxia microenvironment in glioblastoma.

Zhang Y, Zhang B, Lv C, Zhang N, Xing K, Wang Z Theranostics. 2023; 13(11):3744-3760.

PMID: 37441593 PMC: 10334835. DOI: 10.7150/thno.81407.


Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice?.

Wang Y, Strazzabosco M, Madoff D Curr Oncol Rep. 2022; 24(12):1741-1750.

PMID: 36255606 PMC: 10878124. DOI: 10.1007/s11912-022-01338-5.


YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.

Ko S, Kim M, Molina L, Sirica A, Monga S Adv Cancer Res. 2022; 156:283-317.

PMID: 35961703 PMC: 9972177. DOI: 10.1016/bs.acr.2022.02.003.


The Role of the Hedgehog Pathway in Cholangiocarcinoma.

Anichini G, Carrassa L, Stecca B, Marra F, Raggi C Cancers (Basel). 2021; 13(19).

PMID: 34638259 PMC: 8507550. DOI: 10.3390/cancers13194774.


References
1.
Socoteanu M, Mott F, Alpini G, Frankel A . c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 2008; 14(19):2990-4. PMC: 2712164. DOI: 10.3748/wjg.14.2990. View

2.
Razumilava N, Gores G . Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2012; 11(1):13-21.e1. PMC: 3596004. DOI: 10.1016/j.cgh.2012.09.009. View

3.
Mylonis I, Chachami G, Samiotaki M, Panayotou G, Paraskeva E, Kalousi A . Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem. 2006; 281(44):33095-106. DOI: 10.1074/jbc.M605058200. View

4.
Fu O, Hou M, Yang S, Huang S, Lee W . Cobalt chloride-induced hypoxia modulates the invasive potential and matrix metalloproteinases of primary and metastatic breast cancer cells. Anticancer Res. 2009; 29(8):3131-8. View

5.
Katz M, Amit I, Yarden Y . Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta. 2007; 1773(8):1161-76. PMC: 2758354. DOI: 10.1016/j.bbamcr.2007.01.002. View